Pharmabiz1h
BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia
BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...
Taiwan News12h
Down Syndrome Market Size 2024 Industry Analysis, Key Players, Regional Demand, Revenue, Opportunity and Forecast 2032
The global down syndrome market is expected to reach US$ 3,775.8 Million by 2030. The market is expected to experience the growth rate of 17.3% from 2021 to 2030. Request To Download Sample of This ...
Taiwan News12h
Thyroid Cancer Drugs Market Size 2024 Industry Analysis, Key Players, Regional Demand, Revenue, Opportunity and Forecast 2032
Request To Download Sample of This Strategic Report @ Rising cases of thyroid cancer is expected to drive the market. According to National Cancer Institute about 1.2% of men and women are detected ...
LEQEMBI (Lecanemab) For The Treatment Of Alzheimer's Disease Launched In South Korea
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...